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ABSTRACT
HIV patients are exposed to a higher risk of adverse
cardiovascular events, due to complex interactions
between traditional risk factors and HIV infection itself
in terms of ongoing endothelial dysfunctional immune
activation/inflammation and increased risk of
thrombosis. On the other hand, long-span antiretroviral
therapy administration still raises questions on its long-
term safety in an era in which life expectancy is
becoming longer and longer while treatment of non-
HIV-related serious events is increasingly raising
concern. In this article, we will critically analyse the
current knowledge of pathological and clinical aspects
pertaining to the increased risk of cardiovascular
events associated with HIV.
INTRODUCTION
Since the introduction of highly active anti-
retroviral therapy (HAART) for HIV, the
decline in morbidity and mortality has been
troubled by an increasing number of meta-
bolic derangements, including dyslipidaemia,
insulin resistance, abnormalities of glucose
metabolism and changes in fat distribution.1
All these changes occur simultaneously with
HIV infection, increasing the risk of cardio-
vascular (CV) disease. On the other hand,
the long-span antiretroviral (ARV) therapy
administration (such as abacavir or protease
inhibitors (PIs)) still raises questions on its
long-term safety in an era in which life
expectancy is becoming longer and longer
while treatment of non-HIV-related serious
events is increasingly raising concern.2
A recently published meta-analysis,3 4
including observational and randomised con-
trolled trials (RCTs), reported the occurrence
of CV disease (acute coronary syndrome (ACS)
and stroke) among HIV-positive adults. In com-
parison to the HIV-negative population, the
relative risk (RR) of events was higher both for
not-HAART-treated as well as for HAART-
treated patients (RR=1.61 (1.43 to 1.81) and
RR=2.00 (1.70 to 2.37), respectively, all 95%
CI). Moreover, the RR was higher for PI-based
therapies versus non-PI treatments (RR=1.41,
95% CI 1.20 to 1.65).
Two large, prospective observational
cohort studies on HIV-infected patients (the
HIV Outpatient Study (HOPS)5 and Data
collection on Adverse events of Anti-HIV
Drugs (DAD)1 trials) were conducted
between 1996 and 2008. The HOPS showed
that death rates gradually declined from 7
per 100 person-years in 1996, to 2 deaths per
100 person-years after 1999. At the beginning
of the new century, the introduction of novel
ARV therapies led to a twofold increase in
HAART utilisation with about 78% of
patients treated beyond the end of the mil-
lennium (figure 1). Moreover, the same
studies highlighted the growing importance
of heart disease in the last decade, parallel to
a longer life expectancy. Figure 2 depicts the
increasing incidence of CV death as com-
pared with AIDS-related death. In the last
decade, the ratio between these leading
causes of mortality has appeared to plateau,
as confirmed recently in the DAD trial2 (CV
Death/HIV Death ratio=0.39). This phenom-
enon can probably be attributed to the
common event of late presentation to care.
In this context, the complex interaction
between traditional risk factors, comorbid-
ities, drugs and HIV translocation still
remains to be understood (figure 3). Thus,
in this article, we will critically analyse the
current knowledge of pathological and clin-
ical aspects pertaining to the increased risk
of CV events associated with HIV.
HIV and the CV system
Although the mechanism actually remains a
matter of debate, HIV infection has been
shown to increase the risk of coronary
events, although it is very difficult to
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separately appraise the role of the virus and of the
therapy.3 Among 4159 HIV-positive subjects included in
the Keiser Permanente database between 1996 and
2001,6 the hospitalisation rate for CAD as well as the
incidence of acute myocardial infarction (AMI) were sig-
nificantly higher than in HIV-negative participants
(6.5% vs 3.8%, p=0003; 4.3% vs 2.9%, p=0.07 respect-
ively). The larger cohort study7 of almost 4000
HIV-infected patients and more than 1 million controls
reported AMI in 189 HIV and 26 142 non-HIV patients
with an increased rate of AMI per 1000 person-years in
patients with HIV versus those without HIV (11.13%
(95% CI 9.58% to 12.68) vs 6.98% (95% CI 6.89% to
7.06%)) even after adjusting for age, gender, race, hyper-
tension, diabetes and dyslipidaemia. HIV-associated
dyslipidaemia, endothelial damage/dysfunction, inflam-
mation and hypercoagulability, which have been pro-
posed as potential causative mechanisms of increased
risk of events.
Traditional CV risk factors in HIV patients
In the cohort described by Triant et al,7 a significantly
higher prevalence of hypertension (21.2% vs 15.9%),
diabetes (11.5% vs 6.6%) and dyslipidaemia (23.3% vs
17.6%) in HIV-infected patients than the non-HIV
cohort (p<0.0001 for each comparison) was reported.
Data about the prevalence of hypertension in patients
with HIV are conflicting, showing a traditional relation-
ship with dyslipidaemia and initial kidney disease, but
also an unclear causal association with HAART.
Furthermore, HIV-infected men have been recognised
to present a higher prevalence of smoking. On the basis
of the data from the French database,1 by comparison
with the general population, the sex-standardised and
age-standardised morbidity ratio was estimated as 1.5
(95% CI 1.3 to 1.7) overall, 1.4 (95% CI 1.3 to 1.6) in
men and 2.7 (95% CI 1.8 to 3.9) in women. The
increase may be not only due to classical risk factors but
also to exposure to combined ARV treatment, as shown
by Obel et al.8 Furthermore, gender differences have
been widely reported in HIV-positive patients and they
may be related to body weight, risk factors and genetic
differences (several intranuclear receptors involved in
cholesterol metabolism are modulated by sexual hor-
mones): it is accepted that women have a higher risk of
side effects under ARV treatment. Specifically, given the
usually lower body mass index in females, several drugs
may reach higher plasma concentrations potentially asso-
ciated with toxicity.9
The same critical interactions between immunosup-
pression and drugs seem to play a crucial role in devel-
opment of diabetes mellitus. Recently, Boccara et al10
confirmed these observations by reporting the first
occurrence of ACS in HIV-infected patients at a mean
age of 50 years; and male gender and tobacco-smoking
participants as the most prevalent coronary risk factors.
They also reported a much higher proportion of
HIV-infected patients using illicit drugs compared with
HIV-uninfected patients (23% vs 6%; p=0.001). In a
recent meta-analysis performed by our group, we reported
an unexpectedly high incidence of traditional CV risk
factors for such a young population with the exception of
a low prevalence of diabetes (hypertension 22.3% (14.3%
to 30.3%); dyslipidaemia 42.5% (33.4% to 51.6%); hyper-
triglyceridaemia 45.0% (23.7% to 66.4%)).11
Obesity can be highly prevalent in well-controlled
HIV-positive patients since viral factors and ARVs may
both affect fat metabolism. Particularly, visceral fat accu-
mulation is common, and appropriate managing
Figure 2 Cardiovascular (CV)-related/AIDS-related death
ratio and age of death in the HIV Outpatient Study (HOPS)
trial,4 between 1996 and 2004.
Figure 1 Numbers of patients, rate of death (%) and
numbers of patients on highly active antiretroviral therapy
(HAART) in the HIV Outpatient Study (HOPS) trial,4 between
1996 and 2004.
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strategies are warranted given its effect on CV risk.
Furthermore, fat accumulation is a systemic metabolic
abnormality and specific sites (such as epicardial
adipose tissue) have been assessed as markers of CV risk
in HIV-positive and HIV-negative patients.12
HIV infection as a potential aetiological risk factor
Dyslipidaemia
The values of total cholesterol (TC) and high-density
lipoprotein-cholesterol (HDL-C) are rather low in the
early stages of HIV infection. The progressive lowering
of CD4 cell lymphocyte counts (ie, increase activation of
the HIV, which finally destroys these cells) has been asso-
ciated with a reduced clearance of low-density
lipoprotein-cholesterol (LDL-C) particles, lower levels of
apolipoprotein B and a decrease in HDL-C; the
triglyceride levels may positively correlate to the degree
of viraemia. As proposed by Mujawar et al,13 this mechan-
ism derived from deregulations of intracellular lipid
metabolism in HIV-infected macrophages due to the
impairment of the ATP-binding cassette transporter
A1-dependent cholesterol efflux. Conversely, Riddler
et al14 reported, from the multicentre AIDS cohort study,
preseroconversion and post-HAART initiation values of
TC, LDL-C and HDL-C. Before treatment, all these
values substantially decreased (–30, –12 and –22 mg/dL,
respectively) and subsequently, following HAART initi-
ation, both TC and LDL-C increased while insubstantial
change was registered in HDL-C values. These data
provide some evidence that the observed increase in TC
and LDL-C levels could represent, in a portion of sub-
jects, a return to preseroconversion values.
Figure 3 Pathogenesis of atherothrombosis in HIV infection. As shown in the figure, multiple pathways play a role in the
development of the persistent inflammatory status. CMV, cytomegalovirus; HAART, highly active antiretroviral therapy.
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Histologically, the atherosclerosis process in HIV
patients presented different features than in the general
population. As reported by one necroscopic study,15 the
vessel wall seems to be affected circumferentially with an
uncommon prevalence of non-calcified elastic plaque.
Similar findings were reported in studies comparing the
nature of plaques in non-HIV versus HIV-infected men
using coronary CT angiography.16 Additionally, post-
mortem examination studies have shown a high percent-
age of premature and significant atherosclerosis in
young adults and children even before the introduction
of PI therapy.15
Endothelial dysfunction
HIV infection and its complex interaction with the
immune system plays a crucial role leading to increased
cytokine expression and vascular damage. In untreated
(naïve) HIV-infected patients, increased plasma markers
of endothelial dysfunction (ICAM1, ICAM2, ICAM3 and
VCAM1) are already high at diagnosis, without signifi-
cant changes during follow-up.10 In a longitudinal
study,17 participants receiving HAART showed a reduc-
tion in markers of endothelial activation (VCAM1, von
Willebrand factor) that was significantly associated with
plasma HIV RNA levels. Moreover, endothelial function
is also strictly connected with the development of early
atherosclerosis and has been reported to be reduced
even in young HIV-infected people under treatment
when compared with those who are non-infected.18 An
especially impaired endothelial function was reported in
a case of PI regimen administration, probably secondary
to an altered lipid metabolism.19 Notably, Flammer et al
conducted a small RCT (n=39) to clarify if switching
from other PIs to the less atherogenic atazanavir could
improve the endothelial function evaluated as flow-
mediated dilation (FMD) of the brachial artery. They
reported no beneficial impact on vascular endothelium
after switching to an unboosted atazanavir-containing
combination of HAART despite a significant improve-
ment of lipid profile in this arm. Besides, in the
MONARCH RCT,20 switching from triple combination
treatment (darunavir/ritonavir plus two nucleoside
reverse transcriptase inhibitors (NRTIs) to darunavir/
ritonavir monotherapy) did not translate into significant
changes in terms of FMD when regarding endothelial
precursor or circulating endothelial cells. Conversely,
data reported by the AIDS Clinical Trials Group Study in
200821 pointed in the opposite direction, reporting a
similar improvement in endothelial function (FMD) in
all three treatment-naive groups randomly assigned to
receive class-sparing ARV therapy regimens. Among
these 82 participants, the effect on FMD appeared after
4 weeks, and persisted at 24 weeks even after adjusting
for haemodynamic changes or lipid levels. However, as
the authors stated, it is not possible to exclude the fact
that longer and uncontrolled lipid alterations following
long-term HAART ultimately may lead to negative
changes in endothelial activity, and thus potentially
expose participants to a higher CV risk.
Inflammation
Inflammation is associated with endothelial dysfunction
in treated as well as untreated HIV-positive patients.
Accelerated atherosclerosis in HIV infection can occur
in the absence of HAART or detectable viraemia, or
manifest immunodeficiency. High sensitivity C reactive
protein (hsCPR) levels have been shown to be elevated
in patients with HIV compared with healthy participants,
and increased hsCPR levels were also associated with a
higher RR of AMI.22 Hsue et al23 reported on carotid
intima media thickness and levels of hsCRP in two
similar cohorts of HIV-positive versus HIV-negative parti-
cipants, revealing a greater value in all HIV patient
groups, irrespective of the level of viraemia or ARV
therapy even after adjustment for traditional risk factors
(p=0.003). Furthermore, CRP levels remained elevated
in HIV patients. These data suggest that persistent
inflammation may represent the aetiology for early ath-
erosclerosis in these patients. Several investigations have
shown that despite the control of HIV replication below
the assay threshold (20, 40 or 50 copies/mL), HIV repli-
cation (or release from sanctuary sites) persists along
with immune activation.24 Such a chronic and persistent
status, possibly related to viral intestinal damage and
microbial translocation, has been associated with an
increase in soluble markers such as interleukin-6 (IL-6)
and D-dimer.25 Therefore, HIV chronic infection can be
associated with a proinflammatory status that can con-
tribute to plaque formation and damage. Also, a rela-
tionship between hsCPR levels and the risk of cardiac
dysfunction in HIV patients has been described, high-
lighting the role of inflammation, as a consequence of
HIV virions and their harmful effect on cardiomyocytes,
partly by the local release of cytokine.26 27 The ongoing
inflammation probably arises from different mechanisms
including (1) the evolving HIV production (if not HIV
replication); (2) the co-pathogen load of cytomegalo-
virus (CMV) and herpes viruses; (3) the loss of
immune-regulatory T cells; (4) the translocation of lipo-
polysaccharide across a damaged gut mucosa; and (5) the
irreversible fibrosis of the lymphoid infrastructure. CMV
co-infection leads to sustained antigenic stimulation with
potential development of an expanded population of
well-differentiated, apoptosis-resistant, senescent T cells
limiting the immune system in recognised and challenged
novel immune triggers. Recent data in a large Italian
cohort28 report that CMV/HIV co-infection was asso-
ciated with the risk of non-AIDS events/deaths (including
CV events) independently of other prognostic factors,
supporting a potential role of CMV infection in vascular/
degenerative organ disorders commonly associated with
chronic immune activation and ageing.
CMV can promote changes in endothelial cells corre-
sponding to abnormal growth and pathogenesis of ath-
erosclerosis promoted by proangiogenic factors
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including IL-6 and granulocyte macrophage colony
stimulating factor. In a recent review,29 the authors con-
cluded that the relationship between CMV and athero-
sclerosis may reflect a complex interplay between viral
and immunological activation, culminating in cyclical
growth, damage and repair of endothelial cells.
Therefore, closer investigation of the relationship
between CMV and age-related morbidities emerging in
chronic HIV infection appears warranted.
ARV therapy: solution or additive risk factor for CV
disease?
In the past 10 years, several studies have addressed the
question of a possible association between myocardial
infarction and HAART, with controversial results.2 30 31
This heterogeneity arises from study design (observa-
tional cohort studies vs prospective randomised clinical
trials), different populations (age, CV risk factor, previ-
ous exposure to ARV treatment) and also from different
outcome definitions. One of the most relevant and large
studies (the DAD)1 prospectively followed more than
20 000 patients for 94 469 person-years; the RR of myo-
cardial infarction per year of PI exposure was 1.16 (1.10
to 1.23; CI 95%), adjusting for hypertension, diabetes
and non-nucleoside reverse transcriptase inhibitors
(NNRTIs), and remained significant even after adjusting
for serum lipid level.
The Strategies for Management of Antiretroviral
Therapy (SMART) trial,32 one of the largest studies of
HAART interruption, demonstrated that the rate of
major CV events was higher if treatment was interrupted
than with continuous treatment, with a HR of 1.57 (95%
CI 1.0 to 2.46, p=0.05). This association between treat-
ment interruption and coronary events did not appear
to be related to the level of viraemia. These findings
pointed out that suppression of HIV itself plays a main
part in reducing proinflammatory cytokines.
Furthermore, an elevated IL-6 level was significantly asso-
ciated with the development of CV disease (OR=2.8,
p=0.03). Furthermore, in the treatment-interruption
arm, IL-6 and D-dimer were significantly elevated
1 month after randomisation with a strong association
with death (OR=12.6, p<0.0001 for IL-6; OR=13.1,
p<0.0001 for D-dimer).
Protease inhibitors and metabolic complications
Changes in body fat distribution (lipodystrophy includ-
ing both lipoatrophy and lipohypertrophy) are common
in HIV-infected participants and typically start to mani-
fest after 6–12 months of ARV therapy.33 Lipoatrophy
denotes a decrease in adipose tissue volume while lipo-
hypertrophy denotes the opposite, and it commonly
occurs in visceral adipose tissue and in the upper trunk.
This abnormal redistribution of fat has clear clinical
implications such as modifications of body image (thus
affecting medication adherence), ectopic fat distribution
(into the heart and liver tissues, for instance) and, even-
tually, increased CV risk.34 Furthermore, fat
redistribution may also promote insulin resistance
through altered secretion of adipokines and other
inflammatory markers (such as ILs 6, 8 and 10, and
macrophage chemotactic protein-1).
The HIV and HAART associated lipodystrophy is prob-
ably a multifactor in its aetiology arising from HIV infec-
tion itself, affecting both lipid/glucose metabolism and
insulin sensitivity, and producing viral proteins, altering
the activity of glucocorticoid receptors in several tissues.
As recently reported in a registry including more than
800 HIV/AIDS patients, NRTI-based and PI-based regi-
mens were associated with a high risk for developing
lipohypertrophy (OR=2.1, 95% CI 1.7 to 3.3, p<0.01;
OR=6.1, 95% CI 4.1 to 9.7, p<0.01, respectively).35 PIs
have been involved in this process through several path-
ways that include inhibition of apolipoprotein B degrad-
ation, inhibition of insulin signalling pathways and
blocking the function of the glucose transporter
GLUT-4, thus diminishing insulin-stimulated glucose
uptake. Conversely, thymidine analogue regimens (ie,
stavudine, zidovudine) were associated with a high risk
of lipoatrophy.36
The abacavir controversy
Ever since the DAD study reported an association
between the use of the nucleoside reverse transcriptase
inhibitor abacavir and an increase of CV risk in
HIV-1-infected patients, there has been controversy
around this drug.2 Over the years, different studies have
reported disparate results: some cohort studies and a
meta-analysis seemed to confirm the observation,30
whereas other recent studies and another meta-analysis
seemed to contradict this hypothesis.31 Nevertheless, the
major treatment guidelines37 38 warrant caution in the
prescription of this drug in patients already showing a
high CV risk based on traditional parameters.
Nonetheless, a biological mechanism explaining the
reasons for this finding has never been elucidated.
Despite an initial observation of higher levels of inflam-
matory markers in a cross-sectional analysis of samples
from two observational cohorts, subsequent longitudinal
studies failed to detect significant associations between
the use of abacavir and changes in the levels of CV risk
biomarkers (prothrombin fragment F(1+2), D-dimer,
high-sensitivity CRP, IL-8, intercellular adhesion
molecule-1, vascular adhesion molecule-1, E-selectin,
P-selectin, serum amyloid-A and serum amyloid-P). One
of the hypotheses was the higher prevalence of chronic
kidney disease in abacavir-treated patients (being the
most common alternative to the nephrotoxic tenofovir),
thus supporting the increased CV risk.
Characteristics of CAD in HAART-treated patients
As reported in previous paragraphs, for reasons not yet
completely understood, HIV-infected patients on long-
term treatment have a greater prevalence of atheroscler-
otic disease and vascular dysfunction compared with an
age-matched uninfected cohort.39 Additionally, as
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reported in cases of coronary artery disease, patients
tend to manifest an illness with more aggressive
characteristics, with a higher rate of ST-segment eleva-
tion myocardial infarction and multivessel involvement
following the first presentation, as our group recently
reported in a meta-analysis11 of 11 studies including
2442 HIV-patients presenting with ACS. These character-
istics had a higher incidence than in contemporary ACS
registries of non-HIV patients40 and combined together
could in part explain the higher rates of in-hospital
events registered for HIV patients. Conversely, other
studies have reported a more favourable in-hospital
outcome in absence of significant haemodynamic com-
promise.41 However, HIV-infected patients undergoing
percutaneous coronary intervention could be potentially
exposed to a high incidence of non-fatal myocardial
reinfarction, restenosis and in-stent thrombosis, as a
result of a prothrombotic state.
In the report of the Soweto Study Cohort,42 518
HIV-positive patients (mostly HAART-treated) admitted
for a first diagnosis of CV disease between 2006 and
2008, questioned the actual incidence of coronary artery
disease (CAD), reporting a relatively infrequent inci-
dence of ACS (3%). This finding casts doubt on the
potential role of publication bias and confounding
factors in overestimation of HIV and PI exposure risk.
We recently published a large multicentre registry43
including patients presenting with ACS. This cohort of
participants demonstrated a significantly increased risk
for cardiac death in absence of therapy with NRTI as
well as higher risk of AMI in cases of CD4 cell count
<200/mm2. Similar result emerged from another study
recently published by Silverberg et al,44 in which a low
nadir CD4 was the only characteristic associated with
AMI. Conversely, the association between low CD4 nadir
and CV events has been observed in some but not all
studies;4 45 however, patients with a low nadir have
usually been exposed to HIV for several years, have a
blunted immunological recovery and have a higher inci-
dence of HIV-associated and non-associated diseases
including metabolic complications.46 47
These findings strengthen the recommendation of
early HAART treatment initiation. In the occurrence of
coronary syndrome, no other recommendation in HIV
population was provided by current guidelines and up to
now no specific trial subanalysis has been designed to
specifically explore this setting. However, it seems rea-
sonable to analyse the revascularisation strategy carefully
weighing such features as, for example, the stage of HIV
disease and related comorbidities, expected adherence
to therapies, bleeding risk, specific drug–drug interac-
tions (DDIs), etc. In the next paragraph, we summarised
some data regarding the impact of risk factor modifica-
tion and pharmacological treatment.
Modification of risk factors
The early detection and treatment of comorbidities and
modifiable risk factors through lifestyle changes such as
smoking cessation and dietary alterations are likely to
have a significant impact on CV risk in this population.22
Even if HIV infection by itself or with HAART treat-
ment could increase the risk of plaque rupture and
atherothrombosis, routine secondary prevention does
not take into account this challenge. Moreover, LDL
goals are less frequently achieved in HIV-infected patients
during follow-up. A recently published small randomised
trial48 involving 83 HIV patients demonstrated that an
appropriate dietary modification with a moderate reduc-
tion of fat intake (from 31±7% to 21±3% of calories) was
able to prevent the increase in plasma cholesterol,
LDL-C and triglycerides associated with HAART pre-
scription in patients who were previously naïve. These
interventions led to a significant reduction in dyslipidae-
mia after 1 year follow-up (21% vs 68% in control
group; p<0.001), pointing out the central role of a
correct lifestyle modification in this setting. Despite this
fact, a reduction in surrogate markers (lipids) does not
necessarily mean that this will lead to a reduction in
clinical endpoints with such a dietary intervention, also
because this kind of intervention by itself has never
been shown to improve survival.
Furthermore, all HIV care providers should consider
smoking cessation a high priority, considering the high
prevalence of this behaviour and the proven efficacy of
cessation interventions in the HIV population.10
Pharmacological treatment
Dedicated guidelines for the management of hyperlipid-
aemia secondary to HAART have been developed by the
Infectious Disease Society of America (IDSA) and Adult
AIDS Clinical Trials Group (AACTG).49 These recom-
mendations are largely based on National Cholesterol
Education Program Adult Treatment Panel III (NCEP
ATP III) guidelines, and advocate adjusting individual
cholesterol levels through estimation of Framingham
predicted 10-year CV risk. Currently, there is no differ-
ence in hyperlipidaemia target goal treatment between
HIV and non-HIV patients. European Society of
Cardiology/European Atherosclerosis Society 2011 lipid
guidelines50 for the first time pointed out that
HIV-infected patients represent a high-risk group and
need special management. However, the recommenda-
tion was not clear on the goal for LDL-C levels as there
were no trials on whether statins ameliorate CV morbid-
ity and mortality in primary prevention in this specific
population. The key point to consider in the choice of
specific lipid-lowering therapy is the high prevalence of
DDIs in this population. Most ARV drugs have an impact
on drug metabolising enzymes such as cytochrome P450
isoforms (CYP3A4, CYP2B6) and drug transporters
(such as p-glycoprotein and OATP1B1) and therefore
the risk of DDIs is very high.8 The most complete data-
base on this subject is one developed and managed by
the University of Liverpool (available at http://www.
hiv-druginteractions.org). In general PIs (with the excep-
tion of tipranavir), there are potent CYP and OATP1B1
6 Cerrato E, Calcagno A, D’Ascenzo F, et al. Open Heart 2015;2:e000174. doi:10.1136/openhrt-2014-000174
Open Heart
inhibitors suggesting the avoidance of some
lipid-lowering agents or an initial reduced dose.
Therefore, the suggested agents include pravastatin (not
metabolised by CYP3A4), fluvastatin (metabolised
CYP2C9) and pitavastatin (minimally metabolised by
CYP2C9 and glucuronidation). Rosuvastatin concentra-
tions appear to increase when used in combination with
some PIs, thus the suggested starting dose is 10 mg,51
whereas simvastatin and lovastatin administration should
be avoided due to the increased risk of rhabdomyoly-
sis.52 Unfortunately, data concerning a possible role of
statins as a primary prevention treatment are still
lacking. Moreover, CV risk scores, such as Framingham
and other similar systems, did not receive a specific val-
idation for HIV patients. The only device HIV-tailored
and currently available is the DAD 5 Year Estimated Risk
calculator,53 however, further data on its validation are
warranted.
Regarding the prescription of antiplatelet drugs, current
guidelines do not provide specific recommendations in
this setting. However, some data suggested a role of aspirin
in primary prevention in the presence of high CV risk.54
A more complex scenario is represented by the inter-
action between P2Y12 inhibitors (clopidogrel, prasugrel
and ticagrelor) and platelet activity in HIV-treated
patients, mainly depending on specific drug–drug
metabolism. The new P2Y12 agent prasugrel is bioacti-
vated by cytochromes P450 (CYP) 3A/2B6. Ritonavir, a
frequently prescribed PI drug, demonstrated its potential
ability to block prasugrel CYP3A4 bioactivation in vitro
and also in healthy male volunteers.55 Therefore, a reduc-
tion in prasugrel efficiency may be observed in patients,
even if until now there is no specific recommendation for
avoiding this association; whereas no data regarding tica-
grelor in this setting have been reported to date.
Conclusive data regarding how to manage HAART in
the setting of secondary prevention after ACS are sub-
stantially lacking. Most likely, the avoidance of PI regi-
mens after an AMI might be a prudent. Even if the
association with increased incidence of AMI was
observed with cumulative exposure to lopinavir/ritonavir
(and not to atazanavir/ritonavir),56 the whole class has
been associated with impaired lipid and glucose metab-
olism. Certainly further investigation is warranted.
CONCLUSION
In the short-term, ARV therapy has been shown to
reduce CV disease (although this could be simply
related to short time exposition to both virus and ther-
apies); a long-term follow-up is required to determine if
any benefit (or harm) is derived. The results of
ongoing trials will provide important information on
how to manage the timing of HAART initiation opti-
mising risk benefit. The Strategic Timing of
Antiretroviral Treatment (START) trial57 includes
ARV-naive HIV-positive participants with CD4 counts
greater than 500 cells/mm3; it is taking place at about
90 sites in nearly 30 countries where participants are
randomised to either receive ARV treatment immedi-
ately or to defer treatment until their first CD4 count
is less than 350 cells/mm3, or when they have clinical
signs of advanced HIV disease. Such a randomised
study will, therefore, address the question of whether
the purported benefits of early therapy (as is suggested
by the Department of Health and Human Services
guidelines) may overcome the expected drug-
associated side effects.
Other challenges and open issues remain, concerning
the best time to start ARV therapy, the best regimen in
patients with established CAD, the role of anti-
inflammatory and antithrombotic drugs as well as the
long-term clinical outcomes in HIV-positive patients,
‘doomed’ in the modern era to live longer and to face
age-related morbidities.
In conclusion, the purpose of this work is to provide a
‘snapshot’ of current know-how concerning CV risk in
the HIV-infected population even in absence of data
from large registries or randomised clinical trials. We
could not suggest any clear and conclusive recommenda-
tions to the reader on these grounds. Certainly, in our
opinion, only synergic cooperation among different spe-
cialists can be the keystone to better individualisation of
treatment in the chronic and in the acute setting.
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35. Dragović G, Danilovic ́ D, Dimic ́ A, et al. Lipodystrophy induced by
combination antiretroviral therapy in HIV/AIDS patients: a Belgrade
cohort study. Vojnosanit Pregl 2014;71:746–50.
36. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy
under stavudine in HIV-1-infected patients: results of a substudy
from a comparative trial. AIDS 2002;16:2447–54.
37. Panel on Antiretroviral Guidelines for Adults and Adolescents.
Guidelines for the use of antiretroviral agents in HIV-1-infected
adults and adolescents. Department of Health and Human Services,
2012:1–166. http://www.aidsinfo.nih.gov/ContentFiles/Adultan
dAdolescentGL.pdf
38. European AIDS Clinical Society (EACS). Guidelines: clinical
management and treatment of HIV infected adults in Europe,
prevention and management of non-infectious comorbidities in HIV,
version 6.1. 2012. http://www.europeanaidsclinicalsociety.org
39. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular
disease in HIV-infected adults. J Infect Dis 2012;205:S375–82.
40. Jolly SS, Shenkman H, Brieger D, et al. GRACE Investigators.
Quantitative troponin and death, cardiogenic shock, cardiac arrest
and new heart failure in patients with non-ST-segment elevation
acute coronary syndromes (NSTE ACS): insights from the Global
Registry of Acute Coronary Events. Heart 2011;97:197–202.
41. Matetzky S, Domingo M, Kar S, et al. Acute myocardial infarction in
human immunodeficiency virus-infected patients. Arch Intern Med
2003;163:457–60.
42. Sliwa K, Carrington MJ, Becker A, et al. Contribution of the human
immunodeficiency virus/acquired immunodeficiency syndrome
epidemic to de novo presentations of heart disease in the Heart of
Soweto Study cohort. Eur Heart J 2012;33:866–74.
43. D’Ascenzo F, Cerrato E, Appleton D, et al. Prognostic indicators for
recurrent thrombotic events in HIV-infected patients with acute
coronary syndromes: use of registry data from 12 sites in Europe,
South Africa and the United States. Thromb Res 2014;134:558–64.
44. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of
myocardial infarction among HIV-positive individuals with access to
care. J Acquir Immune Defic Syndr 2014;65:160–6.
45. Montlahuc C, Guiguet M, Abgrall S, et al., French Hospital Database
ANRS CO4 cohort. Impact of late presentation on the risk of death
among HIV-infected people in France (2003–2009). J Acquir
Immune Defic Syndr 2013;64:197–203.
46. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with
low CD4/CD8 ratio despite effective antiretroviral therapy exhibit
altered T cell subsets, heightened CD8+ T cell activation, and
8 Cerrato E, Calcagno A, D’Ascenzo F, et al. Open Heart 2015;2:e000174. doi:10.1136/openhrt-2014-000174
Open Heart
increased risk of non-AIDS morbidity and mortality. PLoS Pathog
2014;10:e1004078.
47. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities
in HIV-infected adults. N Engl J Med 2005;352:48–62.
48. Lazzaretti RK, Kuhmmer R, Sprinz E, et al. Dietary intervention
prevents dyslipidemia associated with highly active antiretroviral
therapy in human immunodeficiency virus type 1-infected
individuals: a randomized trial. J Am Coll Cardiol 2012;59:979–88.
49. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Executive summary of the third report of the
National Cholesterol Education Program (NCEP) expert panel on
detection, evaluation, and treatment of high blood cholesterol in
adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
50. Catapano AL, Reiner Z, De Backer G, et al., European Society of
Cardiology (ESC), European Atherosclerosis Society (EAS). ESC/
EAS Guidelines for the management of dyslipidaemias. The Task
Force for the management of dyslipidaemias of the European
Society of Cardiology (ESC) and the European Atherosclerosis
Society (EAS). Atherosclerosis 2011;217:3–46.
51. Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or
fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
J Cardiovasc Pharmacol 2008;51:605–10.
52. Hare CB, Vu MP, Grunfeld C, et al. Simvastatin-nelfinavir interaction
implicated in rhabdomyolysis and death. Clin Infect Dis 2002;35:
e111–12.
53. DAD 5 Year Estimated Risk calculator. http://www.cphiv.dk/tools/
dadriskequations/tabid/437/default.aspx
54. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of
cardiovascular events: an update of the evidence for the US
Preventive Services Task Force. Ann Intern Med 2009;150:405–10.
55. Ancrenaz V, Déglon J, Samer C, et al. Pharmacokinetic interaction
between prasugrel and ritonavir in healthy volunteers. Basic Clin
Pharmacol Toxicol 2013;112:132–7.
56. d’Arminio Monforte A, Reiss P, Ryom L, et al. Atazanavir is not
associated with an increased risk of cardio- or cerebrovascular
disease events. AIDS 2013;27:407–15.
57. Strategic Timing of Antiretroviral Treatment (START). http://
clinicaltrials.gov/ct2/show/NCT00867048
Cerrato E, Calcagno A, D’Ascenzo F, et al. Open Heart 2015;2:e000174. doi:10.1136/openhrt-2014-000174 9
Special populations
